Hirashima N, Itazu I, Nukaya H, Kimura H, Hasegawa I, Yoshimizu T, Nemoto S, Sakakibara K
Dept. of Gastroenterology, Chukyo Hospital.
Gan To Kagaku Ryoho. 1998 May;25(6):873-9.
Patients with unresectable hepatocellular carcinoma (hepatoma) with hypervascularity were treated by SMANCS-TAE. A superselective catheterization technique was used to inject gelatin sponge particles after administration of SMANCS. In 30 patients of first hepatoma treated by SMANCS-TAE. Grade 4 was obtained after 1.7(1-3) courses. The 2-year survival rate was 22%. Some of the 24 patients of second hepatoma treated by SMANCS-TAE have survived over 2 years. Sixteen patients with advanced hepatoma (Vp2-3 or T4) were treated only by SMANCS injection, but none survived over 1 year. SMANCS-TAE appears to have the same potential and safety as L-TAE, when used selectively. Moreover, we can reduce the course of treatment and obtain good QOL for hepatoma patients except in advanced cases.
对无法切除的伴有血管增多的肝细胞癌（肝癌）患者采用丝裂霉素超液化碘油-经动脉栓塞化疗（SMANCS-TAE）治疗。在给予丝裂霉素超液化碘油后，采用超选择性导管插入技术注入明胶海绵颗粒。在30例接受丝裂霉素超液化碘油-经动脉栓塞化疗治疗的原发性肝癌患者中，1.7（1 - 3）个疗程后达到4级。2年生存率为22%。24例接受丝裂霉素超液化碘油-经动脉栓塞化疗治疗的复发性肝癌患者中有部分存活超过2年。16例晚期肝癌（Vp2 - 3或T4）患者仅接受丝裂霉素超液化碘油注射，但无一例存活超过1年。选择性使用时，丝裂霉素超液化碘油-经动脉栓塞化疗似乎与肝动脉栓塞化疗（L-TAE）具有相同的潜力和安全性。此外，除晚期病例外，我们可以减少肝癌患者的治疗疗程并获得良好的生活质量。
